Protein level of CYP2E1 was analyzed by co-immunofluorescence staining immediately after attachment (3h) and 24 hours later. b and c) Protein and mRNA levels of CYP2E1 were analyzed upon TAM pretreatment. d and e) Protein and mRNA levels of catalase were assessed upon TAM pretreatment. Bars represent the means±SD of 3 mice (JPG 3000 KB)
Export PNG
Views: 980 Downloads: 0
Created: 13th Dec 2021 at 09:09
Last updated: 13th Dec 2021 at 09:09
This item has not yet been tagged.
None
Version History
Version 1 (earliest) Created 13th Dec 2021 at 09:09 by Seddik Hammad
No revision comments
Related items
Projects: LiSyM Pillar II: Chronic Liver Disease Progression (LiSyM-DP), LiSyM Pillar III: Regeneration and Repair in Acute-on-Chronic Liver Failure (LiSyM-ACLF), LiSyM network, LiSyM PALs, LiSyM-Krebs Partnering, C-TIP-HCC network
Institutions: Molecular Hepatology - Dept of Medicine II - Medical Faculty Mannheim - Heidelberg University
Liver Systems Medicine : striving to develop non-invasive methods for diagnosing and treating NAFLD by combining mathematical modeling and biological research. LiSyM, is a multidisciplinary research network, in which molecular and cell biologists, clinical researchers, pharmacologists and experts in mathematical modeling examine the liver in its entirety. LiSyM research focuses on the metabolic liver disease non-alcoholic fatty liver disease (NAFLD), which includes non-alcoholic steatohepatitis ...
Projects: LiSyM Core Infrastructure and Management (LiSyM-PD), LiSyM Pillar I: Early Metabolic Injury (LiSyM-EMI), LiSyM Pillar II: Chronic Liver Disease Progression (LiSyM-DP), LiSyM Pillar III: Regeneration and Repair in Acute-on-Chronic Liver Failure (LiSyM-ACLF), LiSyM Pillar IV: Liver Function Diagnostics (LiSyM-LiFuDi), Model Guided Pharmacotherapy In Chronic Liver Disease (LiSyM-MGP), Molecular Steatosis - Imaging & Modeling (LiSyM-MSIM), The Hedgehog Signalling Pathway (LiSyM-JGMMS), Multi-Scale Models for Personalized Liver Function Tests (LiSyM-MM-PLF), LiSyM PALs, Project Management PTJ, LiSyM network, LiSyM Scientific Leadership Team (LiSyM-LT)
Web page: https://www.lisym.org/
In one in five people with NAFLD, the functioning liver cells, the hepatocytes, are replaced by connective tissue. Eventually this fibrosis becomes irreversible. In this state the liver is like a ‘scar that never heals’. Through it, the liver loses many of its vital functions. LiSyM-Pillar II wants to know more about which factors promote fibrosis and the conditions under which fibrosis becomes irreversible How can fibrosis be diagnosed as early as possible? Researchers in the pillar are also ...
Programme: LiSyM: Liver Systems Medicine
Public web page: http://www.lisym.org/our-work/pillar-research
Start date: 1st Jan 2016
Organisms: Mus musculus, Rattus rattus, Rattus norvegicus, Homo sapiens
Pillar II dooley
Snapshots: No snapshots
Snapshots: No snapshots
Submitter: Seddik Hammad
Assay type: Proteomics
Technology type: FACS
Investigation: Julia/Yan
Study: CCl4 Treatment in mice
Organisms: Mus musculus
SOPs: Sample Collection and Preservation of Blood and...
Data files: Movies for quantification, SAC mice RNA microarray, Supp MM 1, Supp fig 3, Supp fig1, Supp fig2, Supplemental Table 1:, Supplemental Table 2, Supplmentary Materials, Methods, Figures and Ta... and 1 hidden item
Snapshots: No snapshots
Abstract (Expand)
Authors: Seddik Hammad, Amnah Othman, Christoph Meyer, Ahmad Telfah, Joerg Lambert, Bedair Dewidar, Julia Werle, Zeribe Chike Nwosu, Abdo Mahli, Christof Dormann, Yan Gao, Kerry Gould, Mei Han, Xiaodong Yuan, Mikheil Gogiashvili, Roland Hergenröder, Claus Hellerbrand, Maria Thomas, Matthias Philip Ebert, Salah Amasheh, Jan G. Hengstler, Steven Dooley
Date Published: 4th Jul 2018
Publication Type: Not specified
DOI: 10.1007/s00204-018-2254-4
Citation: Arch Toxicol 19(11) : 715